Daraxonrasib vs Fenbendazole vs Ivermectin

$480,000/年 vs $234/年 vs $2190/年

Fenben 1500mg/天，$500/1000g，在美国IVM 72mg/天，$1/12mg，在美国

3级及以上不良事件：54% vs 0-1%（估计）vs 0-2%（估计）

“如果伊维菌素有效，制药公司就会使用它”

是的，制药公司正在争相接受：

伊维菌素收入削减99.54%芬苯达唑收入削减99.95%

你现在明白他们为什么如此害怕了吗？

顺便说一句，在Indiamart上以8美分的价格购买伊维菌素，一年的费用大约是$175。

给我找一家癌症药物公司，愿意接受99.54%或99.95%的收入削减。

我的假设是，伊维菌素和芬苯达唑在非小细胞肺癌（NSCLC）中的效果远优于daraxonrasib。而且没有严重的不良事件。

但每位肿瘤学家都在推销这款$480,000的药物，54%的患者会出现严重副作用。

你明白了吗？

这就是为什么佛罗里达州投资超过1.4亿美元用于再利用药物癌症研究。

Daraxonrasib vs Fenbendazole vs Ivermectin

$480,000/year vs $234/year vs $2190/year

Fenben 1500mg/d at $500/1000g in USAIVM 72mg/d at $1/12mg in USA

Grade 3+ adverse events:54% vs 0-1% (est) vs 0-2% (est)

"If Ivermectin worked, pharmaceutical companies would use it"

Yes, pharmaceutical companies are rushing to take:

99.54% revenue cut on Ivermectin99.95% revenue cut on Fenbendazole

Do you see now why they are so AFRAID?

And by the way, Ivermectin bought on Indiamart typically at 8 cents would price out to $175/year.

Show me a Cancer Drug company that is willing to take either a 99.54% or 99.95% revenue cut.

My hypothesis, is that Ivermectin and Fenbendazole give far superior results in NSCLC Lung Cancer than daraxonrasib. Without the severe adverse events.

But every Oncologist is pushing this $480,000 drug with 54% of patients having severe side effects.

DO YOU SEE?

This is why Florida is investing $140+ million into repurposed drug Cancer Research.